SI2101740T1 - Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode - Google Patents

Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode

Info

Publication number
SI2101740T1
SI2101740T1 SI200731398T SI200731398T SI2101740T1 SI 2101740 T1 SI2101740 T1 SI 2101740T1 SI 200731398 T SI200731398 T SI 200731398T SI 200731398 T SI200731398 T SI 200731398T SI 2101740 T1 SI2101740 T1 SI 2101740T1
Authority
SI
Slovenia
Prior art keywords
opioids
pharmaceutical composition
new non
abusable
abusable pharmaceutical
Prior art date
Application number
SI200731398T
Other languages
English (en)
Slovenian (sl)
Inventor
Anders Pettersson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37781988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2101740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of SI2101740T1 publication Critical patent/SI2101740T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731398T 2006-12-04 2007-12-03 Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode SI2101740T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87249606P 2006-12-04 2006-12-04
EP07824784.8A EP2101740B1 (en) 2006-12-04 2007-12-03 New non-abusable pharmaceutical composition comprising opioids
PCT/GB2007/004627 WO2008068471A1 (en) 2006-12-04 2007-12-03 New non-abusable pharmaceutical composition comprising opioids

Publications (1)

Publication Number Publication Date
SI2101740T1 true SI2101740T1 (sl) 2014-03-31

Family

ID=37781988

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731398T SI2101740T1 (sl) 2006-12-04 2007-12-03 Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode

Country Status (9)

Country Link
US (5) US8470361B2 (Direct)
EP (1) EP2101740B1 (Direct)
JP (2) JP5484062B2 (Direct)
DK (1) DK2101740T3 (Direct)
ES (1) ES2439581T3 (Direct)
PL (1) PL2101740T3 (Direct)
PT (1) PT2101740E (Direct)
SI (1) SI2101740T1 (Direct)
WO (1) WO2008068471A1 (Direct)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
PL2101740T3 (pl) 2006-12-04 2014-04-30 Orexo Ab Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
BRPI0917608B8 (pt) 2008-12-12 2021-05-25 Paladin Labs Inc formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
CN102933207B (zh) 2009-10-30 2018-02-02 Ix生物医药有限公司 快速溶解固体剂型
PL2706986T3 (pl) 2011-09-19 2015-08-31 Orexo Ab Nowa niepodatna na nadużywanie kompozycja farmaceutyczna do leczenia uzależnienia od opioidów
SI2849730T1 (sl) * 2012-05-02 2017-02-28 Orexo Ab Novi sestavek alfentanila za zdravljenje akutne bolečine
WO2013164617A1 (en) * 2012-05-02 2013-11-07 Orexo Ab New sufentanil composition for the treatment of acute pain
HK1210599A1 (en) 2012-07-06 2016-04-29 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
CN103304570A (zh) * 2013-07-12 2013-09-18 四川省惠达药业有限公司 一种盐酸纳洛酮化合物、其制备方法及其药物组合物
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
MX2016006087A (es) 2013-11-11 2016-08-12 Impax Laboratories Inc Formulaciones de desintegracion rapida y metodos de uso.
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3177146A4 (en) 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
PL3344248T3 (pl) 2015-09-02 2022-07-18 Trevena, Inc. Zawierające sześcioczłonowy aza-heterocykl związki modulujące receptor opioidowy delta oraz sposoby ich wykorzystywania i wytwarzania
EP3210630A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
CA3048360C (en) * 2016-12-26 2021-06-29 Shionogi & Co., Ltd. Production method for formulation having improved content uniformity
KR102662065B1 (ko) 2017-02-17 2024-05-07 트레베나, 인코포레이티드. 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
KR20190129867A (ko) 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
EP4100012A4 (en) 2020-02-05 2024-02-07 Summit Biosciences Inc. MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES
EP4548911A1 (en) 2023-11-06 2025-05-07 Extrovis AG Pharmaceutical compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5138412A (en) 1974-09-24 1976-03-31 Nippon Kayaku Kk Kokoseizai no seiho
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
FR2562313B1 (fr) 1984-04-03 1989-04-07 Cogema Procede de decontamination en uranium et en radium de solutions uraniferes acides par addition d'un sel d'aluminium
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
ES2539904T3 (es) 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
AU2002305559B2 (en) 2001-05-11 2008-04-03 Mundipharma Pty Limited Abuse-resistant controlled-release opioid dosage form
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
SI1587514T1 (sl) 2003-01-31 2006-10-31 Orexo Ab Hitro ucinkujoc farmacevtski sestavek
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
KR20080002788A (ko) 2005-03-28 2008-01-04 오렉쏘 에이비 통증 치료용 약학 조성물
PL2101740T3 (pl) 2006-12-04 2014-04-30 Orexo Ab Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy

Also Published As

Publication number Publication date
US20130195982A1 (en) 2013-08-01
DK2101740T3 (da) 2013-11-18
US20140335190A1 (en) 2014-11-13
US8658198B2 (en) 2014-02-25
WO2008068471A1 (en) 2008-06-12
JP2013249312A (ja) 2013-12-12
US20100129443A1 (en) 2010-05-27
US20160151351A1 (en) 2016-06-02
US20130195981A1 (en) 2013-08-01
EP2101740B1 (en) 2013-11-06
PT2101740E (pt) 2013-12-23
JP2010511683A (ja) 2010-04-15
PL2101740T3 (pl) 2014-04-30
US8980305B2 (en) 2015-03-17
JP5484062B2 (ja) 2014-05-07
US8470361B2 (en) 2013-06-25
EP2101740A1 (en) 2009-09-23
ES2439581T3 (es) 2014-01-23

Similar Documents

Publication Publication Date Title
PL2101740T3 (pl) Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy
ZA200808530B (en) Pharmaceutical composition for external use
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
ZA200808531B (en) Pharmaceutical composition for external use
GB0713625D0 (en) Pharmaceutical compositions
PL2124556T3 (pl) Kompozycje farmaceutyczne
IL198651A0 (en) COMPOSITION COMPRISING (-)-Ôêå9-TRANS-TETRAHYDROCANNABIONOL
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
GB0607605D0 (en) Composition
EP2059135A4 (en) NOVEL COMPOSITION
HU0600097D0 (en) Pharmaceutical composition comprising tacrolimus
GB0600032D0 (en) Pharmaceutical composition
GB0612696D0 (en) Pharmaceutical composition
GB0617578D0 (en) Pharmaceutical composition
HU0600939D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions
GB0611079D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions
GB0622964D0 (en) Pharmaceutical compositions
HU0600938D0 (en) Pharmaceutical compositions
GB0625433D0 (en) Pharmaceutical combinations
GB0614457D0 (en) Pharmaceutical Combinations
GB0619768D0 (en) Pharmaceutical composition comprising antibodies